Creating a new chip to study cancer spread using blood samples
Development of Next-Generation Blood-to-barcode (B2B) chip for In Vivo CRISPR-Based Discovery of Metastasis Regulators
['FUNDING_R01'] · NORTHWESTERN UNIVERSITY · NIH-11032730
This study is looking for patients to help test a new blood test that uses advanced technology to find out how cancer spreads in the body, which could lead to better treatments for stopping it.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHWESTERN UNIVERSITY (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-11032730 on ClinicalTrials.gov |
What this research studies
This research focuses on developing an innovative blood-to-barcode chip that utilizes CRISPR technology to identify genetic factors involved in cancer metastasis. By analyzing circulating tumor cells (CTCs) found in the bloodstream, the project aims to uncover the genetic programs that drive cancer spread, which is a major cause of cancer-related deaths. The approach involves capturing these rare cells and amplifying their genetic material for detailed analysis, providing insights that could lead to new anti-metastatic therapies. Patients may have the opportunity to contribute blood samples to help advance this important work.
Who could benefit from this research
Good fit: Ideal candidates for this research include cancer patients, particularly those with metastatic disease or those at risk of metastasis.
Not a fit: Patients with non-cancerous conditions or those whose cancer is not expected to metastasize may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new treatments that specifically target and inhibit cancer metastasis, improving survival rates for patients.
How similar studies have performed: While the use of CRISPR technology in cancer research is gaining traction, this specific approach utilizing a blood-to-barcode chip for CTC analysis is relatively novel and has not been extensively tested.
Where this research is happening
Chicago, UNITED STATES
- NORTHWESTERN UNIVERSITY — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KELLEY, SHANA O — NORTHWESTERN UNIVERSITY
- Study coordinator: KELLEY, SHANA O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.